CART-38（University of Pennsylvania）

N/A

Report date: 2025/06/27 20:00:57

Base Information

Drug NameCART-38（University of Pennsylvania）

Drug Alias NameCART-38

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CD38Anti-Tumor necrosis factor receptor superfamily member 9

TargetsLymphocyte differentiation antigen CD38Tumor necrosis factor receptor superfamily member 9

Therapy Area/IndicationsMultiple MyelomaLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Pennsylvania

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesUniversity Of Pennsylvania

Active IndicationsN/A

Inactive IndicationsMultiple MyelomaLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A